Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexza completes target enrollment in migraine trial
The trial involves approximately 160 migraine patients with or without aura. Three doses of AZ-104 (1.25mg, 2.5mg and 5mg) were evaluated against placebo in the clinical trial. Using
The trial involves approximately 160 migraine patients with or without aura. Three doses of AZ-104 (1.25mg, 2.5mg and 5mg) were evaluated against placebo in the clinical trial. Using
This Phase II study is the first in a number of further clinical studies planned for the anticancer vascular-disrupting agent CYT997 and will be conducted at the Alfred
In June 2006, GlaxoSmithKline’s (GSK’s) Center of Excellence for External Drug Discovery and Galapagos initiated a program to deliver disease-modifying drugs with clinical proof of concept to GSK’s
According to RaySearch, Compass is a state-of-the-art solution for quality assurance in radiotherapy used to measure and reconstruct the 3D radiation dose that was actually delivered to the
Lorcaserin is Arena’s Phase III oral drug candidate being developed for the treatment of obesity. The agreements with Siegfried include: a long-term supply agreement for Arena’s purchase of
Cognizant will extend its existing relationship with Merck, dating back to 2005, to become a key technology partner and provide a full suite of services encompassing applications outsourcing,
The primary endpoint of the study is the objective tumor response or lack of early disease progression. The trial is expected to enroll approximately 30 patients at a
The antibody was developed using Medarex’s UltiMAb technology and is the fifth UltiMAb-derived antibody in clinical development by Amgen, including two UltiMAb antibodies in Phase II clinical studies.
Bystolic is a once-daily medication that can be used alone or in combination with other hypertension treatments. Forest licensed US and Canadian rights to Bystolic (nebivolol) from Mylan
The supplemental biological license application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for Orencia. Jung-Jin Seo, chairman and CEO of Celltrion, said: “We